Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2025 (Report No. 3)
Date of Filing: March 18, 2025
This filing serves to distribute a press release regarding the presentation of six studies featuring the Company's ProSense® Cryoablation technology at the St. Gallen International Breast Cancer Conference.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on corporate news and does not contain financial statements or quantitative financial data.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The primary update is the dissemination of clinical study presentations at a major international conference.
Guidance, Outlook, and Management Commentary
Management Commentary: The Company highlighted the inclusion of its ProSense® Cryoablation technology in six studies presented at the St. Gallen International Breast Cancer Conference.
Outlook and Risks: The filing text does not provide specific forward-looking guidance, risk factors, or contingencies beyond the context of the clinical study presentations.
Key Facts for Investor Verification
- Verify the specific findings and outcomes of the six studies presented at the St. Gallen International Breast Cancer Conference.
- Review the full text of the press release (Exhibit 99.1) for details on the clinical data.
- Confirm the incorporation of this press release into the Company's active Registration Statements on Form F-3 and Form S-8.
- Note that this filing contains no financial performance data; refer to the most recent Form 20-F for financial metrics.